Purdue Pharma Bankruptcy Plan Rejected by Supreme Court, Billionaire Sacklers to Face Lawsuits
Purdue Pharma Bankruptcy Plan Rejected by Supreme Court, Billionaire Sacklers to Face Lawsuits
The Supreme Court has rejected a bankruptcy plan for OxyContin-maker Purdue Pharma that would have allocated billions from the wealthy Sackler family to combat opioid addiction, and the Sacklers would have been shielded from civil lawsuits related to their alleged role in the opioid crisis.
最高法院拒绝了美国痛经药制造商普渡制药公司的破产计划，该计划本应将亿万富豪萨克勒家族的数十亿资产用于打击阿片类药物成瘾问题，而且萨克勒家族的所谓涉嫌引发阿片类药物危机的民事诉讼将会被保护。
The 5-4 decision marks a victory for a minority of opioid victims who voted against the settlement to continue pressing lawsuits against the Sackler family.
这项5-4的决定是阿片类药物受害者的少数人的胜利，他们投票反对和解，继续对萨克勒家族提起诉讼。
It is a setback for most victims and state and local governments who have accepted the settlement.
这是大多数受害者以及接受了和解的州和地方政府的挫败。
The Wall Street Journal notes the ruling is among the highest-profile bankruptcy decisions ever from the high court, significantly weakening the ability of corporations and their insiders to use bankruptcy to resolve mass litigation.
《华尔街日报》指出，这一裁决是最高法院有史以来最具影响力的破产案例之一，极大削弱了公司及其内部人员使用破产来解决大规模诉讼的能力。
Purdue Pharma, which introduced OxyContin in the late 1990s and made billions from the prescription painkiller, faced thousands of opioid lawsuits by 2019.
普渡制药公司在20世纪90年代末推出痛经药奥斯康定，并从这种处方药中赚取了数十亿美元，到2019年面临着数千起阿片类药物诉讼案。
The company filed for Chapter 11 protection, though the Sackler family did not declare bankruptcy and moved much of their wealth to offshore trusts.
该公司申请了第11章破产保护，但萨克勒家族并未宣布破产，而是将大部分财富转移到了离岸信托基金中。
They agreed to pay $6 billion to settle civil claims, denying wrongdoing and arguing their settlement was the best way to fund addiction-fighting initiatives.
他们同意支付60亿美元以解决民事索赔，否认有任何不当行为，并声称他们的和解是资助防治成瘾计划的最佳途径。
In 2021, a New York bankruptcy court approved a reorganization plan for Purdue.
2021年，纽约一个破产法庭批准了普渡制药公司的重组计划。
The WSJ report added that this plan included funds from the Sacklers' offshore trusts and ceded the company and its assets to creditors.
《华尔街日报》的报道还提到，该计划包括从萨克勒家族的离岸信托基金中获得的资金并将公司及其资产移交给债权人。
Most funds would go to state and local governments for opioid-related programs, with $750 million shared among roughly 130,000 individual opioid claimants.
大多数资金将用于州和地方政府的阿片类药物相关项目，750万美元将分配给大约13万名阿片类药物索赔人。
While nearly all claimants accepted the plan, it required dissenters to accept immunity for the Sacklers from ongoing and future litigation, which many viewed as inadequate compensation.
虽然几乎所有的索赔人都接受了该计划，但反对者必须接受对萨克勒家族的豁免，而这被许多人认为是不充足的补偿。
The Justice Department opposed Purdue's plan, arguing it would unlawfully extinguish individuals' rights to pursue civil lawsuits.
司法部反对普渡公司的计划，认为该计划将非法地取消个人追求民事诉讼的权利。
The Office of the U.S. Trustee appealed to the Supreme Court, stating that the plan gave the Sacklers an unprecedented release from liability.
美国受托人办公室向最高法院上诉，称该计划给予萨克勒家族前所未有的免责权。
Purdue lawyers argued that the third-party release was necessary under U.S. bankruptcy law to secure the Sacklers' $6 billion contribution.
普渡制药公司的律师辩称，第三方免责是根据美国破产法必要的，以确保萨克勒家族提供60亿美元的捐款。
Purdue lawyer Gregory Garre stated that blocking the settlement would result in the evaporation of funds for opioid abatement and compensation, leaving creditors and victims with nothing and potentially costing lives.
普渡公司的律师格雷戈里·加雷表示，阻止和解将导致用于防止成瘾和赔偿的资金消失，使债权人和受害者毫无所获，甚至会造成生命的损失。
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
免责声明：本文部分内容使用了Benzinga Neuro的帮助。此内容是通过AI工具部分制作的，并由Benzinga编辑进行了审查和发布。
Photo via Shutterstock
图片来自shutterstock。